Indirect Treatment Comparison of ARIA Outcomes for Lecanemab Compared to Donanemab Based on Reported Results

Abstract

Background: Although both anti‐amyloid monoclonal antibodies have demonstrated slowed disease progression in mild cognitive impairment and mild dementia due to Alzheimer's disease, lecanemab and donanemab have different mechanisms of action and, consequently, safety profiles.

The paper